These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 1355523)

  • 1. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.
    Markman M; Rowinsky E; Hakes T; Reichman B; Jones W; Lewis JL; Rubin S; Curtin J; Barakat R; Phillips M
    J Clin Oncol; 1992 Sep; 10(9):1485-91. PubMed ID: 1355523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.
    Francis P; Rowinsky E; Schneider J; Hakes T; Hoskins W; Markman M
    J Clin Oncol; 1995 Dec; 13(12):2961-7. PubMed ID: 8523061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraperitoneal administration of Taxol in the management of ovarian cancer.
    Markman M; Rowinsky E; Hakes T; Reichman B; Jones W; Lewis JL; Rubin S; Curtin J; Barakat R; Almadrones L
    J Natl Cancer Inst Monogr; 1993; (15):103-6. PubMed ID: 7912515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.
    Armstrong DK; Fleming GF; Markman M; Bailey HH
    Gynecol Oncol; 2006 Nov; 103(2):391-6. PubMed ID: 16626792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.
    Sarosy G; Kohn E; Stone DA; Rothenberg M; Jacob J; Adamo DO; Ognibene FP; Cunnion RE; Reed E
    J Clin Oncol; 1992 Jul; 10(7):1165-70. PubMed ID: 1376773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.
    Morgan RJ; Doroshow JH; Synold T; Lim D; Shibata S; Margolin K; Schwarz R; Leong L; Somlo G; Twardowski P; Yen Y; Chow W; Lin P; Paz B; Chu D; Frankel P; Stalter S
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5896-901. PubMed ID: 14676112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancer.
    Markman M; Francis P; Rowinsky E; Hakes T; Reichman B; Jones W; Lewis JL; Rubin S; Curtin J; Barakat R
    Ann Oncol; 1994; 5 Suppl 6():S55-8. PubMed ID: 7865436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of taxol given by a 6-hour intravenous infusion.
    Brown T; Havlin K; Weiss G; Cagnola J; Koeller J; Kuhn J; Rizzo J; Craig J; Phillips J; Von Hoff D
    J Clin Oncol; 1991 Jul; 9(7):1261-7. PubMed ID: 1675263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taxol: an important new drug in the management of epithelial ovarian cancer.
    Markman M
    Yale J Biol Med; 1991; 64(6):583-90. PubMed ID: 1687343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients.
    Chambers SK; Chambers JT; Davis CA; Kohorn EI; Schwartz PE; Lorber MI; Handschumacher RE; Pizzorno G
    J Clin Oncol; 1997 May; 15(5):1945-52. PubMed ID: 9164206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacodynamic study of taxol in refractory acute leukemias.
    Rowinsky EK; Burke PJ; Karp JE; Tucker RW; Ettinger DS; Donehower RC
    Cancer Res; 1989 Aug; 49(16):4640-7. PubMed ID: 2568175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of taxol administered as a short i.v. infusion daily for 5 days.
    Grem JL; Tutsch KD; Simon KJ; Alberti DB; Willson JK; Tormey DC; Swaminathan S; Trump DL
    Cancer Treat Rep; 1987 Dec; 71(12):1179-84. PubMed ID: 2891442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of taxol given as a 3-hour infusion every 21 days.
    Kris MG; O'Connell JP; Gralla RJ; Wertheim MS; Parente RM; Schiff PB; Young CW
    Cancer Treat Rep; 1986 May; 70(5):605-7. PubMed ID: 2871928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.
    McGuire WP; Rowinsky EK; Rosenshein NB; Grumbine FC; Ettinger DS; Armstrong DK; Donehower RC
    Ann Intern Med; 1989 Aug; 111(4):273-9. PubMed ID: 2569287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal paclitaxel: a possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma.
    Kodera Y; Ito Y; Ito S; Ohashi N; Mochizuki Y; Yamamura Y; Koike M; Fujiwara M; Nakanishi H; Nakao A
    Hepatogastroenterology; 2007; 54(75):960-3. PubMed ID: 17591103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraperitoneal paclitaxel in the management of ovarian cancer.
    Markman M
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):86-7. PubMed ID: 7481868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical and pharmacokinetic study of taxol.
    Wiernik PH; Schwartz EL; Strauman JJ; Dutcher JP; Lipton RB; Paietta E
    Cancer Res; 1987 May; 47(9):2486-93. PubMed ID: 2882837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
    Markman M; Liu PY; Wilczynski S; Monk B; Copeland LJ; Alvarez RD; Jiang C; Alberts D; ;
    J Clin Oncol; 2003 Jul; 21(13):2460-5. PubMed ID: 12829663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.
    Markman M; Brady MF; Spirtos NM; Hanjani P; Rubin SC
    J Clin Oncol; 1998 Aug; 16(8):2620-4. PubMed ID: 9704711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.
    Meerpohl HG; du Bois A; Kühnle H; Lück HJ; Kreienberg R; Möbus V; Bauknecht T; Köchli O; Bochtler H; Diergarten K
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):7-12. PubMed ID: 8643973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.